新型冠状病毒肺炎患者肝损伤的原因及保肝药物治疗  

Causes of liver injury in patients with COVID-19 and treatment with hepatoprotective drugs

作　　者：张津 张文静 ZHANG Jin;ZHANG Wenjing(Department of Pharmacy,Changhai hospital,Naval Medical University,Shanghai 200433,China;Tenth People´s Hospital Affiliated to Tongji University,shanghai 200072,China)

机构地区：[1]海军军医大学附属长海医院药学部,上海200433 [2]同济大学附属第十人民医院,上海200072

出　　处：《药学实践杂志》2020年第6期481-484,共4页Journal of Pharmaceutical Practice

基　　金：上海市卫生计生委重要薄弱学科建设项目(2016ZB0303-01)。

摘　　要：新型冠状病毒(SARS-CoV-2)感染引起的新型冠状病毒肺炎(COVID-19)患者临床表现出不同程度的肝损伤。一系列研究表明细胞因子风暴、SARS-CoV-2病毒所致的胆管细胞损伤以及药物性肝毒性可以诱导继发性肝损伤,对不同因素所致的肝损伤的机制以及保肝药物治疗进行综述,以期为后续深入揭示该方面的研究提供参考支持。COVID-19 patients infected with SARS-CoV-2 showed different degrees of liver injury.A series of studies have shown that cytokine storm,bile duct cell injury caused by SARS-CoV-2 and drug-induced hepatotoxicity can induce secondary liver injury.This article will review the mechanism of liver injury caused by different factors and the treatment of hepatoprotective drugs,in order to provide reference support for further research in this field.

关 键 词：新型冠状病毒 新型冠状病毒肺炎 肝损伤 炎性反应 细胞因子风暴 

分 类 号：R97[医药卫生—药品]